Improving the outcome of umbilical cord blood transplantation through ex vivo expansion or graft manipulation

Cytotherapy

Volumn 17, Issue 6, 2015, Pages 730-738

  Horwitz, Mitchell E ^a   Frassoni, Francesco ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON; CHELATING AGENT; COMPLEMENT COMPONENT C3A; COPPER; NOTCH RECEPTOR; PROSTAGLANDIN E2;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; CELL HOMING; CELL POPULATION; CLINICAL EFFECTIVENESS; COCULTURE; CORD BLOOD STEM CELL TRANSPLANTATION; COST EFFECTIVENESS ANALYSIS; ENGRAFTMENT; EX VIVO STUDY; FUCOSYLATION; GRAFT FAILURE; GRAFT MANIPULATION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; LIVING DONOR; LYMPHOCYTE COUNT; MEDICAL PROCEDURES; MESENCHYME CELL; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL EXPANSION; T LYMPHOCYTE; TREATMENT RESPONSE; ADULT; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; FETUS BLOOD; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; TREATMENT OUTCOME;

ADULT; CELL PROLIFERATION; CHELATING AGENTS; COCULTURE TECHNIQUES; CORD BLOOD STEM CELL TRANSPLANTATION; FETAL BLOOD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; RECEPTORS, NOTCH; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84929049174     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.02.004     Document Type: Review

References (49)

1. Frassoni F., Gualandi F., Podesta M., Raiola A.M., Ibatici A., Piaggio G., et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 2008, 9:831-839.
2. Brunstein C.G., Barker J.N., Weisdorf D.J., Defor T.E., McKenna D., Chong S.Y., et al. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant 2009, 43:935-940.
3. Liu H., Rich E.S., Godley L., Odenike O., Joseph L., Marino S., et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 2011, 118:6438-6445.
4. Peffault de Latour R., Brunstein C.G., Porcher R., Chevallier P., Robin M., Warlick E., et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biol Blood Marrow Transplant 2013, 19:1355-1360.
5. Smith A.R., Baker K.S., Defor T.E., Verneris M.R., Wagner J.E., Macmillan M.L. Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors. Biol Blood Marrow Transplant 2009, 15:1086-1093.
6. Jaroscak J., Goltry K., Smith A., Waters-Pick B., Martin P.L., Driscoll T.A., et al. Augmentation of umbilical cord blood (UCB) transplantation with exvivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. Blood 2003, 101:5061-5067.
7. Cristy M. Active bone marrow distribution as a function of age in humans. Phy Med Biol 1981, 26:389-400.
8. Kim D.K., Fujiki Y., Fukushima T., Ema H., Shibuya A., Nakauchi H. Comparison of hematopoietic activities of human bone marrow and umbilical cord blood CD34 positive and negative cells. Stem Cells 1999, 17:286-294.
9. Scaradavou A., Brunstein C.G., Eapen M., Le-Rademacher J., Barker J.N., Chao N., et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood 2013, 121:752-758.
10. Barker J.N., Weisdorf D.J., DeFor T.E., Blazar B.R., McGlave P.B., Miller J.S., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005, 105:1343-1347.
11. Milner L.A., Kopan R., Martin D.I., Bernstein I.D. Ahuman homologue of the Drosophila developmental gene, Notch, is expressed in CD34+ hematopoietic precursors. Blood 1994, 83:2057-2062.
12. Delaney C., Varnum-Finney B., Aoyama K., Brashem-Stein C., Bernstein I.D. Dose-dependent effects of the Notch ligand Delta1 on exvivo differentiation and invivo marrow repopulating ability of cord blood cells. Blood 2005, 106:2693-2699.
13. Gutman J.A., Turtle C.J., Manley T.J., Heimfeld S., Bernstein I.D., Riddell S.R., et al. Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood 2010, 115:757-765.
14. Moretta A., Andriolo G., Lisini D., Martinetti M., Pasi A., Rebulla P., et al. Invitro evaluation of graft-versus-graft alloreactivity as a tool to identify the predominant cord blood unit before double cord blood transplantation. Biol Blood Marrow Transplant 2012, 18:1108-1118.
15. Delaney C. Infusion of non-HLA matched, off-the-shelf exvivo expanded cord blood progenitor cells in patients undergoing myeloablative cord blood transplantation is safe and decreases the time to neutrophil recovery. Biol Blood Marrow Transplant 2012, 18:S203.
16. Peled T., Landau E., Mandel J., Glukhman E., Goudsmid N.R., Nagler A., et al. Linear polyamine copper chelator tetraethylenepentamine augments long-term exvivo expansion of cord blood-derived CD34+ cells and increases their engraftment potential in NOD/SCID mice. Exp Hematol 2004, 32:547-555.
17. Peled T., Mandel J., Goudsmid R.N., Landor C., Hasson N., Harati D., et al. Pre-clinical development of cord blood-derived progenitor cell graft expanded exvivo with cytokines and the polyamine copper chelator tetraethylenepentamine. Cytotherapy 2004, 6:344-355.
18. de Lima M., McMannis J., Gee A., Komanduri K., Couriel D., Andersson B.S., et al. Transplantation of exvivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant 2008, 41:771-778.
19. Stiff P.J., Montesinos P., Peled T., Landau E., Rosenheimer N., Mandel J., et al. StemEx (copper chelation based) exvivo expanded umbilical cord blood stem cell transplantation (UCBT) accelerates engraftment and improves 100 day survival in myeloablated patients compared to a registry cohort undergoing double unit UCBT: results of a multicenter study of 101 patients with hematologic malignancies. Blood 2013, 122:3060.
20. Peled T., Shoham H., Aschengrau D., Yackoubov D., Frei G., Rosenheimer G.N., et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol 2012, 40:342-355. e1.
21. Horwitz M.E., Chao N.J., Rizzieri D.A., Long G.D., Sullivan K.M., Gasparetto C., et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. JClin Invest 2014, 124:3121-3128.
22. Briddell R.A., Hartley C.A., Smith K.A., McNiece I.K. Recombinant rat stem cell factor synergizes with recombinant human granulocyte colony-stimulating factor invivo in mice to mobilize peripheral blood progenitor cells that have enhanced repopulating potential. Blood 1993, 82:1720-1723.
23. McNiece I., Harrington J., Turney J., Kellner J., Shpall E.J. Exvivo expansion of cord blood mononuclear cells on mesenchymal stem cells. Cytotherapy 2004, 6:311-317.
24. de Lima M., McNiece I., Robinson S.N., Munsell M., Eapen M., Horowitz M., et al. Cord-blood engraftment with exvivo mesenchymal-cell coculture. NEngl J Med 2012, 367:2305-2315.
25. Boitano A.E., Wang J., Romeo R., Bouchez L.C., Parker A.E., Sutton S.E., et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010, 329:1345-1348.
26. Wagner JE, Brunstein C, McKenna D, Sumstad D, Moohs S, Laughlin M, etal. StemRegenin-1 (SR1) Expansion Culture Abrogates the Engraftment Barrier Associated with Umbilical Cord Bood Transplantation. Abstract to be presented at the 56th American Society of Hematology Meeting and Exposition.2014.
27. North T.E., Goessling W., Walkley C.R., Lengerke C., Kopani K.R., Lord A.M., et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007, 447:1007-1011.
28. Cutler C., Multani P., Robbins D., Kim H.T., Le T., Hoggatt J., et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 2013, 122:3074-3081.
29. Ratajczak J., Reca R., Kucia M., Majka M., Allendorf D.J., Baran J.T., et al. Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood 2004, 103:2071-2078.
30. Reca R., Mastellos D., Majka M., Marquez L., Ratajczak J., Franchini S., et al. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood 2003, 101:3784-3793.
31. Brunstein C.G., McKenna D.H., DeFor T.E., Sumstad D., Paul P., Weisdorf D.J., et al. Complement fragment 3a priming of umbilical cord blood progenitors: safety profile. Biol Blood Marrow Transplant 2013, 19:1474-1479.
32. Hidalgo A., Weiss L.A., Frenette P.S. Functional selectin ligands mediating human CD34(+) cell interactions with bone marrow endothelium are enhanced postnatally. JClin Invest 2002, 110:559-569.
33. Robinson S.N., Thomas M.W., Simmons P.J., Lu J., Yang H., Parmar S., et al. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy 2014, 16:84-89.
34. Xia L., McDaniel J.M., Yago T., Doeden A., McEver R.P. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood 2004, 104:3091-3096.
35. Jacobson C.A., Turki A.T., McDonough S.M., Stevenson K.E., Kim H.T., Kao G., et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:565-574.
36. Kanda J., Chiou L.W., Szabolcs P., Sempowski G.D., Rizzieri D.A., Long G.D., et al. Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:1664-1676. e1.
37. Rocha V., Labopin M., Sanz G., Arcese W., Schwerdtfeger R., Bosi A., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. NEngl J Med 2004, 351:2276-2285.
38. Berglund S., Gertow J., Magalhaes I., Mattsson J., Uhlin M. Cord blood T cells cultured with IL-7 in addition to IL-2 exhibit a higher degree of polyfunctionality and superior proliferation potential. JImmunother 2013, 36:432-441.
39. Davis C.C., Marti L.C., Sempowski G.D., Jeyaraj D.A., Szabolcs P. Interleukin-7 permits Th1/Tc1 maturation and promotes exvivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation. Cancer Res 2010, 70:5249-5258.
40. Hanley P.J., Cruz C.R., Savoldo B., Leen A.M., Stanojevic M., Khalil M., et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009, 114:1958-1967.
41. Park K.D., Marti L., Kurtzberg J., Szabolcs P. Invitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood 2006, 108:1770-1773.
42. Safdar A., Decker W.K., Li S., Xing D., Robinson S.N., Yang H., et al. De novo T-lymphocyte responses against baculovirus-derived recombinant influenzavirus hemagglutinin generated by a naive umbilical cord blood model of dendritic cell vaccination. Vaccine 2009, 27:1479-1484.
43. Wagner J.E., Eapen M., Carter S., Wang Y., Schultz K.R., Wall D.A., et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. NEngl J Med 2014, 371:1685-1694.
44. Cohen J.L., Trenado A., Vasey D., Klatzmann D., Salomon B.L. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. JExp Med 2002, 196:401-406.
45. Hoffmann P., Ermann J., Edinger M., Fathman C.G., Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. JExp Med 2002, 196:389-399.
46. Taylor P.A., Noelle R.J., Blazar B.R. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. JExp Med 2001, 193:1311-1318.
47. Brunstein C.G., Miller J.S., Cao Q., McKenna D.H., Hippen K.L., Curtsinger J., et al. Infusion of exvivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011, 117:1061-1070.
48. Delaney C., Heimfeld S., Brashem-Stein C., Voorhies H., Manger R.L., Bernstein I.D. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nature Medicine 2010, 16:232-236.
49. Robinson S.N., Simmons P.J., Thomas M.W., Brouard N., Javni J.A., Trilok S., et al. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rgamma(null) mice. Exp Hematol 2012, 40:445-456.